Switzerland's Addex Q1 net loss widens
Switzerland's Addex Q1 net loss widens
Overview
Switzerland biopharma firm's Q1 income fell and net loss widened yr/yr
R&D and G&A expenses both declined from prior year
Company highlighted progress of Neurosterix's Phase 1 study for schizophrenia candidate
Outlook
Company did not provide specific financial or operational guidance
Result Drivers
R&D EXPENSES DOWN - R&D expenses declined mainly due to reduced zero-cost services from Neurosterix’s Group
G&A EXPENSES DOWN - G&A expenses decreased mainly due to lower professional fees, partly offset by higher staff costs
Company press release: ID:nGNE1pbTpj
Key Details
Metric | Beat/Miss | Actual | Consensus Estimate |
Q1 EPS |
| -CHF 0.01 |
|
Q1 Net Income |
| -CHF 1.71 mln |
|
Q1 Operating Income |
| -CHF 480,000 |
For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.
(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)